by Mybiogate | Sep 30, 2020 | Industry Research
Author: Youwen Dai Recently, I visited several senior executives of pharmaceutical companies in China. A large proportion of companies visited reported that they plan to in-license respiratory-related products and optimize product pipelines to cope with the... 
by Mybiogate | Sep 28, 2020 | Industry Research
Author: MJ Yuan With the popularization of anti-aging treatments, for some people simple cosmetic modification is not sufficient. There is a growing preference for more permanent aesthetic medicine methods. Frost & Sullivan data show that China has become... by vivek | Sep 27, 2020 | China Market
China has a long history with ophthalmology, eye care, through traditional Chinese medicine practices, but as technology advances, so must research and medical practices to ensure that the best and most successful treatments possible are available. In the past,... by vivek | Sep 27, 2020 | China Market
As a global push for developing pediatric medicine continues, more research and clinical trials are being given the opportunity to advance. While an imperative body of medicine, pediatric drugs have historically been underserved. In China, this unsaturated market is... 
by Mybiogate | Sep 25, 2020 | Chinese company profile
Harbin Pharmaceutical Group Co., Ltd. 2019 Revenue: US$ 17.33 Billion Number of Employees: 20,000 Founded: 1971 Overview Harbin Pharmaceutical Group Co., Ltd. (HPGC) is a China-based Sino-foreign equity joint venture, principally engaged in pharmaceutical...